Markman M, Cleary S, Pfeifle C, Howell S B
Cancer. 1986 Jul 1;58(1):18-21. doi: 10.1002/1097-0142(19860701)58:1<18::aid-cncr2820580105>3.0.co;2-c.
Twenty-one patients with malignant mesothelioma were treated with an experimental intracavitary chemotherapy regimen of weekly intraperitoneal or intrapleural cisplatin (90-100 mg/m2) with simultaneous intravenous sodium thiosulfate delivered to protect against cisplatin-induced nephrotoxicity. One of eight patients (12.5%) receiving intrapleural therapy and nine of 13 patients receiving intraperitoneal therapy demonstrated objective evidence of a clinical response, including three surgically defined major tumor regressions (23%). Patients receiving intrapleural treatment had more advanced disease prior to therapy than those receiving intraperitoneal therapy. It was concluded that intraperitoneal cisplatin is an active treatment program for intra-abdominally localized mesothelioma. Additional investigation of intrapleural cisplatin should be undertaken in a patient population with less advanced disease or following surgical debulking.
21例恶性间皮瘤患者接受了一种实验性腔内化疗方案，即每周腹腔内或胸腔内注射顺铂（90 - 100mg/m²），同时静脉注射硫代硫酸钠以预防顺铂诱导的肾毒性。接受胸腔内治疗的8例患者中有1例（12.5%），接受腹腔内治疗的13例患者中有9例表现出临床反应的客观证据，包括3例手术确定的主要肿瘤消退（23%）。接受胸腔内治疗的患者在治疗前的疾病比接受腹腔内治疗的患者更晚期。得出的结论是，腹腔内顺铂是治疗腹腔内局限性间皮瘤的一种有效治疗方案。对于疾病不太晚期或手术减瘤后的患者群体，应进一步研究胸腔内顺铂治疗。
